Tepezza (teprotumumab-trbw) is a prescription biologic medicine used to treat thyroid eye disease (TED) in adults. It is a monoclonal antibody that targets and inhibits the insulin-like growth factor-1 receptor (IGF-1R), which plays a role in the inflammation and tissue changes associated with TED. Tepezza is administered as a series of intravenous infusions and may help reduce eye bulging (proptosis), improve double vision, and relieve other symptoms associated with thyroid eye disease.